Tuesday, March 26, 2013

China Hospital Industry Development and Investment Study 2012-2015

China hospital industry has maintained stable growth in recent years, thanks to the market demand stimulus and stable influx of national investment. As of late 2011, China had a total of 21,979 hospitals, with the AAGR of 2.7% during 2005-2011. In particular, the proportion of non-public hospitals grew to 39.4%. In 2011, the revenue of China hospital industry totaled RMB1.2451 trillion, with the CAGR as high as 19.7%, while the gross margin was no more than 3.8%.  

In recent years, Chinese government has unveiled a series of favorable policies to boost the reform of public hospitals, encourage and guide social capitals to rush into hospital industry. This move resulted in further maturity of investment operation mode of China hospital industry. Since 2010, privately-owned hospitals including Hong Kong Phoenix International Investment Group, YMCI, SL PHARM, Xi'an Kaiyuan Investment Group Company Limited and Jinling Pharmaceutical Company Limited have been restructured through trusteeship and M&A by public hospitals, while foreign enterprises have run their business in China via joint business, joint stock and joint venture, with orientation to Chinese top-grade medical market. Cases in point include United Family Hospital and ParkwayHealth.
At present, the specialized hospitals in China are much favored in the marketization trend and little exposed to policy risk, thus, they are one of highlights when it comes to social capital investment. In 2011, the number of specialized hospitals in China surged from 2,682 in 2005 to 4,283, among which privately-owned ones accounting for 59.4%. And the revenue generated by the specialized hospitals amounted to RMB139.1bilion, with the CAGR in 2005-2011 reached 22.2% while the average gross margin realized 12.1%. In particular, the gross margin generated by ophthalmic hospitals and Cosmetic hospitals claimed 14.7% and 12.8%, respectively. In 2011, the gross margin of Aier Eye Hospital Group, TC Medical, and Mayinglong Pharm, the leading privately-run specialized hospitals in China, reported 55.3%, 47.2% and 39.4%, respectively.   
To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis/165067

The report highlights the followings: 

  • China hospital industry market overview: number of hospitals of all sorts, operation, status quo of medical service, competition pattern, etc.  
  • current development of specialized hospitals in China: overall operation, operation of ophthalmic hospitals, stomatological hospitals, plastic surgery hospitals, beauty hospitals, maternity hospitals, Children’s hospitals, and tumour hospitals as well as their development outlook;
  • development prediction of China hospital industry: status quo of China medical security, boosting urbanization’s influence on China healthcare market, supply and demand of medical resources in 2015;
  • investment in China hospital industry: related polices on social capital flowing into the hospital industry, operational efficiency comparison between privately-owned hospitals and public ones;
  • present operation, investment, mergers and development prediction of four major privately-owned specialized hospitals in China, six listed companies that have accessed into the hospital industry, and two foreign hospitals.

Related Report:

Assessing Solvency II - Challenges and Opportunities for the Insurance Industry

Reasons To Buy
  • Make strategic business decisions using this detailed assessment of the key challenges and opportunities
  • Understand directives of the new regulations and necessary changes required in the current business structure of a firm, in order to be prepared for smooth implementation  
  • Assess the adoption of Solvency II in different countries
  • Find out how the key segments of the insurance industry will be impacted in the short run and the long run
  • Understand the impact on key asset classes due to the change in regulations 

No comments:

Post a Comment